{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:41:18Z","timestamp":1763037678997,"version":"3.44.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"am","delay-in-days":440,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bulcan.2021.04.022","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T11:32:39Z","timestamp":1639567959000},"page":"S28-S39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S","title":["CAR-T cells dans les lymphomes\u00a0: actualit\u00e9s r\u00e9centes"],"prefix":"10.1016","volume":"108","author":[{"given":"Ondine","family":"Mess\u00e9ant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6617-9371","authenticated-orcid":false,"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2021.04.022_bib0185","first-page":"23","article-title":"Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990\u00a0et 2018","volume":"2","author":"Le","year":"2019","journal-title":"Hemopathies Malignes"},{"issue":"16","key":"10.1016\/j.bulcan.2021.04.022_bib0190","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1\u00a0study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2021.04.022_bib0195","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3324\/haematol.2012.072090","article-title":"Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant","volume":"98","author":"Van Den Neste","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bulcan.2021.04.022_bib0200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2019000736","article-title":"Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT","volume":"4","author":"Badar","year":"2020","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.bulcan.2021.04.022_bib0205","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2021.04.022_bib0210","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"year":"2020","series-title":"Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel [Online]","author":"Jacobson","key":"10.1016\/j.bulcan.2021.04.022_bib0220"},{"year":"2020","series-title":"Myc Expression and Tumor-Infiltrating T Cells Are Associated With Response in Patients With Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (r\/r DLBCL) Treated With Tisagenlecleucel in the JULIET Trial [Online]","author":"Jaeger","key":"10.1016\/j.bulcan.2021.04.022_bib0215"},{"issue":"10254","key":"10.1016\/j.bulcan.2021.04.022_bib0255","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2021.04.022_bib0225","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720902899","article-title":"Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas","volume":"11","author":"Riedell","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"21","key":"10.1016\/j.bulcan.2021.04.022_bib0230","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bulcan.2021.04.022_bib0235","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2\u00a0trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.bulcan.2021.04.022_bib0240","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.bulcan.2021.04.022_bib0180","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.bulcan.2021.04.022_bib0245","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood-2019-124750","article-title":"Post-Marketing Use Outcomes of an Anti-CD19\u00a0Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)","volume":"134","author":"Pasquini","year":"2019","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bulcan.2021.04.022_bib0250","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"year":"2020","series-title":"Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study [Online]","author":"Godwin","key":"10.1016\/j.bulcan.2021.04.022_bib0260"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2021.04.022_bib0265","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2020-134449","article-title":"Interim Analysis of ZUMA-12: A Phase 2\u00a0Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)","volume":"136","author":"Neelapu","year":"2020","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2021.04.022_bib0270","doi-asserted-by":"crossref","first-page":"TPS7585","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7585","article-title":"ZUMA-7: A phase 3\u00a0randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed\/refractory diffuse large B cell lymphoma (R\/R DLBCL)","volume":"36","author":"Oluwole","year":"2018","journal-title":"J Clin Oncol"},{"year":"2020","series-title":"CD58\u00a0Aberrations Limit Durable Responses to CD19\u00a0CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering. [Online]","author":"Majzner","key":"10.1016\/j.bulcan.2021.04.022_bib0275"},{"issue":"3","key":"10.1016\/j.bulcan.2021.04.022_bib0280","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1016\/j.bbmt.2018.12.314","article-title":"End of Phase 1\u00a0Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma","volume":"25","author":"Jacobson","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"10.1016\/j.bulcan.2021.04.022_bib0285","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.bulcan.2021.04.022_bib0290","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19\u00a0CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"year":"2020","series-title":"One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19\u00a0in Patients with Relapsed\/Refractory Mantle Cell Lymphoma [Online]","author":"Wang","key":"10.1016\/j.bulcan.2021.04.022_bib0295"},{"year":"2020","series-title":"Safety and Preliminary Efficacy in Patients with Relapsed\/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001 [Online]","author":"Palomba","key":"10.1016\/j.bulcan.2021.04.022_bib0300"},{"year":"2020","series-title":"Primary Analysis of Zuma-5: A Phase 2\u00a0Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed\/Refractory (R\/R) Indolent Non-Hodgkin Lymphoma (iNHL) [Online]","author":"Jacobson","key":"10.1016\/j.bulcan.2021.04.022_bib0305"},{"year":"2020","series-title":"Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed\/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2\u00a0ELARA Trial [Online]","author":"Fowler","key":"10.1016\/j.bulcan.2021.04.022_bib0310"},{"issue":"32","key":"10.1016\/j.bulcan.2021.04.022_bib0315","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30\u00a0CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2021.04.022_bib0320","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bulcan.2021.04.022_bib0325","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11899-020-00590-5","article-title":"Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma","volume":"15","author":"Rogers","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"year":"2020","series-title":"12th Annual T-Cell Lymphoma Forum","author":"Beaven","key":"10.1016\/j.bulcan.2021.04.022_bib0330"},{"issue":"Supplement_1","key":"10.1016\/j.bulcan.2021.04.022_bib0335","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2019-129559","article-title":"Safety and Anti-Tumor Activity of CD5\u00a0CAR T-Cells in Patients with Relapsed\/Refractory T-Cell Malignancies","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2021.04.022_bib0340","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2021.04.022_bib0345","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2020.38.15_suppl.8002","article-title":"First-in-human data of ALLO-501\u00a0and ALLO-647\u00a0in relapsed\/refractory large B-cell or follicular lymphoma (R\/R LBCL\/FL): ALPHA study","volume":"38","author":"Neelapu","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2021.04.022_bib0350","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.04.022_bib0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.00888","article-title":"The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice","volume":"11","author":"Cerrano","year":"2020","journal-title":"Front Immunol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121002502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121002502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:36:13Z","timestamp":1757792173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121002502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0007455121002502"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.04.022","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cells dans les lymphomes\u00a0: actualit\u00e9s r\u00e9centes","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}